5.82 0.00 (0.00%)
Pre-Market: 6:47AM EST
Previous Close | 5.45 |
Open | 5.75 |
Bid | 0.00 x 1800 |
Ask | 5.96 x 1400 |
Day's Range | 5.70 - 6.28 |
52 Week Range | 1.27 - 10.97 |
Volume | 531,128 |
Avg. Volume | 457,553 |
Market Cap | 77.849M |
Beta (5Y Monthly) | 0.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.20 |
Earnings Date | May 15, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
NEW YORK, NY / ACCESSWIRE / February 24, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Cleveland BioLabs, Inc. (NASDAQ:CBLI) relating to the creation of a combined company between the Company and Cytocom, Inc.
BUFFALO, NY / ACCESSWIRE / February 23, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has closed its previously announced registered direct offering for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.
BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.